This is a ready-to-use technology transfer report that closes the loop on a transfer plan: what was compared against what acceptance criteria, what passed, what didn’t and how it was resolved, and a documented decision on whether the transfer is complete. Replace every <<FILL: ...>> placeholder with your own specifics and route it through your normal document control, review, and approval. A worked filled specimen follows. Verify each cited reference against the current source before you rely on it.
Document control header
| Field | Entry |
|---|---|
| Document title | Technology Transfer Report for <<FILL: product / process>> |
| Document number | <<FILL: e.g. TTR-2026-05>> |
| Version | <<FILL>> |
| Effective date | <<FILL>> |
| Sending site / Receiving site | <<FILL>> / <<FILL>> |
| Linked transfer plan | <<FILL: TTP-ID>> |
| Linked risk assessment | <<FILL: RA-ID>> |
| Linked gap assessment | <<FILL: GA-ID>> |
1. Purpose
This report closes the technology transfer plan referenced above. It summarizes what was compared between sending and receiving sites, states the outcome against each acceptance criterion in the plan, documents deviations and their resolution, and records the formal decision on whether the transfer is complete.
2. Scope
State the process, methods, and sites covered, matching the scope stated in the linked transfer plan. Note any scope change since the plan was approved and why.
3. Summary of activities performed
| Activity | Reference document | Status |
|---|---|---|
| Process knowledge transfer | <<FILL>> | <<FILL>> |
| Gap assessment | <<FILL: GA-ID>> | <<FILL>> |
| Risk assessment | <<FILL: RA-ID>> | <<FILL>> |
| Analytical method transfer | <<FILL>> | <<FILL>> |
| Engineering run(s) | <<FILL: protocol/report IDs>> | <<FILL>> |
| PPQ readiness review | <<FILL>> | <<FILL>> |
4. Results against acceptance criteria
| Acceptance criterion (from transfer plan section 8) | Result | Met? |
|---|---|---|
| Process performance at receiving site meets predefined criteria against established CQAs | <<FILL>> | Yes / No |
| Analytical methods validated, verified, or transferred, with the transfer protocol executed and closed | <<FILL>> | Yes / No |
| Receiving-site operators and analysts demonstrated independent performance | <<FILL>> | Yes / No |
| Deviations trended, not just individually closed, nothing pointing at an unresolved systemic issue | <<FILL>> | Yes / No |
| Any CAPA opened during the transfer closed with verified effectiveness | <<FILL>> | Yes / No |
| Process control strategy and master production instructions reflect the receiving site’s actual equipment | <<FILL>> | Yes / No |
5. Deviations and resolutions
| Deviation ID | Description | Root cause | Resolution | Closed? |
|---|---|---|---|---|
<<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
<<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
State whether the pattern of deviations, taken together, points at anything systemic the individual closures might have missed.
6. Analytical comparability summary (if applicable)
Summarize the comparability outcome under ICH Q5E where the transfer required it: which quality attributes were compared, whether results fell within predefined equivalence criteria, and whether any attribute required a documented rationale for an out-of-range but accepted result. State the comparability protocol reference rather than repeating its data in full.
7. Conclusion and transfer status
| Field | Entry |
|---|---|
| Overall conclusion | <<FILL: transfer complete / complete with follow-up commitments / not complete>> |
| Open follow-up commitments, if any | <<FILL: item, owner, due date>> |
| Regulatory filing impact | <<FILL: none / IND-CTA amendment / PAS / CBE-30, reference>> |
| Quality unit acceptance | <<FILL: name, date>> |
A transfer report is not the raw data set; it is the conclusion someone can act on. State plainly whether the receiving site can now run and control the process independently.
8. References
ICH Q5E, Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process. ICH Q9(R1), Quality Risk Management. ICH Q10, Pharmaceutical Quality System.
Confirm the current version of each reference before issue.
9. Revision history
| Version | Date | Author | Summary of change |
|---|---|---|---|
<<FILL: 1.0>> | <<FILL>> | <<FILL>> | Initial issue. |
10. Approvals
| Role | Name | Signature | Date |
|---|---|---|---|
| Author (Transfer lead) | <<FILL>> | ||
| Sending site process owner | <<FILL>> | ||
| Receiving site process owner | <<FILL>> | ||
| Approver (QA) | <<FILL>> | ||
| Regulatory affairs (filing impact confirmed) | <<FILL>> |
Filled specimen
Extract from an example transfer of Acme Therapeutics’ ATX-207 lentiviral-vector CAR-T process from the clinical manufacturing site to a CDMO for the pivotal program. Company, product, and numbers are illustrative.
| Acceptance criterion | Result | Met? |
|---|---|---|
| Process performance at receiving site meets predefined criteria against established CQAs | Two engineering runs and one PPQ-track batch met all CQA acceptance criteria; viral vector titer fell within the sending-site historical range on both engineering runs after the reference-material bridging study closed | Yes |
| Analytical methods validated, verified, or transferred, with the transfer protocol executed and closed | qPCR titer method transferred via comparative testing plus a reference-material bridging study; report ATM-2026-018 approved | Yes |
| Receiving-site operators and analysts demonstrated independent performance | Independent-performance qualification completed for all four assigned operators during engineering run 2 | Yes |
Deviation DEV-2026-0142: engineering run 1 titer result approximately 30 percent below the sending site’s historical range, on a split sample of the same vector lot tested at both labs. Root cause: the receiving lab’s qPCR standard curve used a different reference material lot than the one qualified at the sending site, identified through the after-action review’s fixed agenda item reviewing any result trending toward a limit. Resolution: a bridging study comparing both reference material lots confirmed the discrepancy sat in the reference material rather than the vector itself; a documented equivalency was accepted in place of a full assay revalidation. Closed, verified by engineering run 2 titer results falling within range using the corrected reference material.
Conclusion: transfer complete. No open follow-up commitments. Regulatory filing impact: none for the CDMO addition at this stage; a CTA site amendment was filed and cleared before the pivotal batch was manufactured. Quality unit acceptance recorded by the receiving site QA director.
Common inspection findings this report prevents
- A transfer declared “complete” verbally or by email, with no signed report stating the basis for that conclusion.
- A report that restates the plan’s intent rather than the actual results against each acceptance criterion.
- Deviations closed individually with no statement of whether the pattern, taken together, points at something systemic.
- A report silent on regulatory filing impact, leaving the question unanswered until an inspector asks.
- A transfer report whose conclusion does not match the batch disposition history that follows it.
How to adapt this report
- Set your document number and link it explicitly to the transfer plan, risk assessment, and gap assessment it closes.
- Populate section 4 against the exact acceptance criteria stated in the transfer plan, not a generic list.
- Report every deviation opened during the transfer, not only the ones that required a formal investigation.
- State the regulatory filing impact explicitly, even when the answer is “none,” rather than leaving the field blank.
- Do not sign section 10 until the batch disposition history for any batches made since the transfer confirms the conclusion still holds.